We designed a multivalent sulfonate with an FDA-approved cyclodextrin core that can bind strongly to the HSPG (Heparan sulfate proteoglycan) receptor on the outer shell of the virus and eventually lead to the irreversible deformation of the virus. In-vitro and ex-vivo test showed the molecule was effective against many heparan sulfate-based viruses, including HIV, RSV, the Dengue, Zika and hepatitis, at micromolar concentration. Moreover, the molecule showed no toxicity and passed the virus resistance test. Recent tests on a model virus analogous to SARS-CoV-2 further suggested its effectiveness against SARS-CoV-2.
Addressing target audiences and expressing needs
- Grants and Subsidies
- Other blended financing
- Business partners – SMEs, Entrepreneurs, Large Corporations
- Incubators / Accelerators
- Marketing Mentoring or Coaching
- Financing Expertise
- Technology Transfer Expertise
- Legal / IPR advise
- Investor readiness training
- Investor introductions
- Business plan development
- Expanding to more markets /finding new customers
- Executive Training
- Collaboration
- Business Angels
- Venture Capital
- Crowd-funding Equity
- Other type of Investment
We are looking for collaborations with groups and institutes that can provide SARS-CoV-2 animal models and specialists in pharmaceutical preparation. We also need partners to work on PK/PD, toxicity, efficiency studies and eventually clinical trials in the future.
- Public or private funding institutions
- Other Actors who can help us fulfil our market potential
- Research and Technology Organisations
- Academia/ Universities
- Private Investors
Result submitted to Horizon Results Platform by ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
